Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARV-6723 |
| Synonyms | |
| Therapy Description |
ARV-6723 is a small molecule proteolysis-targeted chimera (PROTAC) that targets MAP4K1 (HPK1) for degradation, potentially resulting in decreased tumor growth (Cancer Immunol Res (2026) 14 (2_Supplement): C041). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARV-6723 | ARV6723|ARV 6723 | MAP4K1 Inhibitor 9 | ARV-6723 is a small molecule proteolysis-targeted chimera (PROTAC) that targets MAP4K1 (HPK1) for degradation, potentially resulting in decreased tumor growth (Cancer Immunol Res (2026) 14 (2_Supplement): C041). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07749586 | Phase Ib/II | ARV-6723 + Pembrolizumab ARV-6723 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |